2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Investing.com -- Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron ...

Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...

After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company ...

Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...

US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as ...

Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reduced by 425,744 shares, marking a 63.01% reduction and a -0.96% impact on the ...

The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...

Skorney covers the Healthcare sector, focusing on stocks such as Regeneron, Soleno Therapeutics, and Biohaven Ltd.. TipRanks tracks over 100,000 company insiders, identifying the select few who excel ...